Company intelligence / Profile preview

Topigen Pharmaceuticals

Montreal, Quebec, Canadatopigen.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Topigen’s lead candidate ASM8 was in Phase II clinical development for moderate-to-severe asthma. TPI 1100 was a preclinical candidate for COPD. ASM8 showed an attractive clinical profile but no detailed efficacy results are available in public sources. TPI 1020 completed a Phase II study with good safety/tolerability but insufficient activity; development focus shifted to TPI 1100.

Therapeutic areas: PulmonologyDermatologyOphthalmologyImmunology
Modalities: oligonucleotides (multi-targeted RNA-silencing oligonucleotide technology)
Industry: Biotech

Drug pipeline

2 assets

TPI 1020

Phase 2

Indications: Chronic Obstructive Pulmonary Disease

1 more asset in the full pipeline.

Request access →

Partnerships

NicOx S.A. (licensed anti-inflammatory drug TPI1020 from NicOx)

Beyond the preview

Go deeper on Topigen Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Topigen Pharmaceuticals.

Explore the full profile